L-citrulline
Phase 3Small molecule
L-citrulline is a supplement that helps improve blood flow and may enhance physical performance and sexual function. It works by increasing nitric oxide levels in the body, which helps blood vessels relax and widen.[1] L-citrulline is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
L-citrulline is one of 125 small molecule programs targeting Vascular Disease. It is currently in Phase 3.
5
Indications
21
Total Trials
5
Active Trials
124
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1L-citrulline
AAsklepion Pharmaceuticals, LLC
Phase 3
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
DUPIXENT
RegeneronPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease5 trials
Acute Lung Injury2 trials
Bronchopulmonary Dysplasia2 trials
Intravenous2 trials
8 more indications
Respiratory Failure1 trial
MELAS1 trial
L-Citrulline Dose Finding Safety Study in MELAS
Completed·—·Phase 1·NCT03952234·10 enrolled
Peripheral Arterial Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-citrulline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAsklepion Pharmaceuticals, LLC